Literature DB >> 25253263

Expression of CD64 on neutrophils can be used to predict the severity of bloodstream infection before broad range 16S rRNA PCR.

David Stubljar1, Miha Skvarc.   

Abstract

The aging population and increased incidence of severe bacterial infection can lead to sepsis. Interest to early identification of endangered patients and identification of pathogen do not always confirm the infection. To use biomarkers can help in early identification of infection and opportunity to start therapy timeously. All biomarkers were defined in 33 out of 96 patients. Thirty-two (97 %) patients had bacterial infection and 1 (3 %) patient had systemic inflammatory response syndrome (SIRS) without infection. PCR confirmed the infection in 27 cases and blood cultures in 8. Area under curve (AUC) for CD64 was 1.00, meanwhile other biomarkers showed 2-fold smaller AUC for positive infection. CD64 index was associated with bacterial infection (p<0.001) and could be used to confirm assessment of SIRS severity (p=0.037). As regards to our results, limited to only 33 patients, CD64 index served as a good parameter to predict bacterial infection and determine severity. The use of broad range 16S ribosomal RNA (rRNA) PCR proved to be an excellent tool to confirm bloodstream infection. The CD64 index had the highest AUC, which exceeded all the others, and could be used to predict the outcome of broad range 16S rRNA PCR from whole blood. However, C-reactive protein (CRP), procalcitonin (PCT) and sCD14 are much easier and faster to measure, but the values could be elevated in other clinical assessments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25253263     DOI: 10.1007/s12223-014-0346-y

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  40 in total

1.  Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria.

Authors:  C B Chiwakata; C Manegold; L Bönicke; I Waase; C Jülch; M Dietrich
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

2.  Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS).

Authors:  S S Qureshi; S M Lewis; V A Gant; D Treacher; B H Davis; K A Brown
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis.

Authors:  Yasunori Yaegashi; Kamon Shirakawa; Nobuhiro Sato; Yasushi Suzuki; Masahiro Kojika; Satoko Imai; Gaku Takahashi; Michiko Miyata; Shoji Furusako; Shigeatsu Endo
Journal:  J Infect Chemother       Date:  2005-10       Impact factor: 2.211

4.  Procalcitonin as a prognostic biomarker of severe sepsis and septic shock.

Authors:  José Raimundo Araujo de Azevedo; Orlando Jorge Martins Torres; Nicolau Gregori Czeczko; Felipe Francisco Tuon; Paulo Afonso Nunes Nassif; Gleim Dias de Souza
Journal:  Rev Col Bras Cir       Date:  2012-12

5.  Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome.

Authors:  Tatsuyori Shozushima; Gaku Takahashi; Naoya Matsumoto; Masahiro Kojika; Yoshikazu Okamura; Shigeatsu Endo
Journal:  J Infect Chemother       Date:  2011-05-12       Impact factor: 2.211

Review 6.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

7.  In critically ill patients the procalcitonin level can be misleading.

Authors:  Jacqueline Koeze; M G Ron Hendrix; Frank A J T M van den Bergh; René M L Brouwer; Jan G Zijlstra
Journal:  Crit Care       Date:  2011-04-28       Impact factor: 9.097

8.  Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study.

Authors:  Shigeatsu Endo; Yasushi Suzuki; Gaku Takahashi; Tatsuyori Shozushima; Hiroyasu Ishikura; Akira Murai; Takeshi Nishida; Yuhei Irie; Masanao Miura; Hironobu Iguchi; Yasuo Fukui; Kimiaki Tanaka; Tsuyoshi Nojima; Yoshikazu Okamura
Journal:  J Infect Chemother       Date:  2012-06-13       Impact factor: 2.211

9.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

10.  Comparative assessment of cytokines and other inflammatory markers for the early diagnosis of neonatal sepsis-a case control study.

Authors:  Akila Prashant; Prashant Vishwanath; Praveen Kulkarni; Prashanth Sathya Narayana; Vijaykumar Gowdara; Suma M Nataraj; Rashmi Nagaraj
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

View more
  2 in total

1.  Expression of CD11c and EMR2 on neutrophils: potential diagnostic biomarkers for sepsis and systemic inflammation.

Authors:  S M Lewis; D F Treacher; J Edgeworth; G Mahalingam; C S Brown; T A Mare; M Stacey; R Beale; K A Brown
Journal:  Clin Exp Immunol       Date:  2015-09-22       Impact factor: 4.330

2.  The Utility of Neutrophil CD64 and Presepsin as Diagnostic, Prognostic, and Monitoring Biomarkers in Neonatal Sepsis.

Authors:  Heba E Hashem; Rania M Abdel Halim; Sherin A El Masry; Amira M Mokhtar; Noureldin M Abdelaal
Journal:  Int J Microbiol       Date:  2020-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.